{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-037125","form_type":"8-K","ticker":"DNTH","cik":"0001690585","company_name":"Dianthus Therapeutics, Inc. /DE/","filed_at":"2025-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.460348+00:00","generated_at":"2026-05-24T23:47:04.373767+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Dianthus reports FY2024 net loss $85M; Phase 2 gMG top-line on track for 2H'25","bullets":["Net loss of $85.0M ($2.55 per share) in FY2024, vs $43.6M ($8.45 per share) in FY2023.","Cash, cash equivalents and investments of $357.0M as of Dec 31, 2024, providing runway into 2H'27.","R&D expenses rose to $83.1M from $32.8M, driven by clinical and CMC costs for DNTH103.","Phase 2 MaGic gMG trial on track for top-line results in 2H'25; Phase 3 CIDP interim analysis in 2H'26.","Appointed John C. King as CCO and Sujay Kango to Board on March 5, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-037125","json":"https://secwatch.observer/filing/0000950170-25-037125.json","markdown":"https://secwatch.observer/filing/0000950170-25-037125.md","text":"https://secwatch.observer/filing/0000950170-25-037125.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1690585/000095017025037125/0000950170-25-037125-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1690585/000095017025037125/dnth-20250311.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T23:47:04.373767+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}